Medical device and pharmaceutical company Derma Sciences (DSCI) closes its 3.521M share secondary offering at a price of $10.34 per share, which includes the exercise of the underwriters' option to purchase 459,300 shares to cover over-allotments. Total net proceeds to the company were approximately $33.8M, for which it plans to use the funds for the continued development of its drug candidate DSC127 for the treatment of diabetic foot ulcers, in addition to other general corporate purposes.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs